CompletedNCT03402152
NRX-101 and a Brain Biomarker in Depression During Bipolarity
About this title
Read the official source — NCT03402152Medication studyAges 18–65United StatesSuicide prevention
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateStarted: November 1, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 8
- Sponsor
- NeuroRx, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03402152
- Official title
Show the full official title
Validation of the Glx Biomarker for Treatment of Moderate Bipolar Depression With NRX-101
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New York
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is NeuroRx, Inc.
Did this study involve medication?
Yes. The study involved medication, including NRX-101, Lurasidone HCl and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
